Lava Therapeutics B.V. is a biotech company that develops proprietary Vγ9Vδ2 T-cell engagers based on the scientific advancements of the VU University Medical Center in Amsterdam.

The objective is to develop cost-effective next-generation immune oncology biopharmaceuticals delivering the primary targeted treatment in combination with immune recruiting and activating functionality.